DALLAS, March 17, 2016 -- Blue Calypso, Inc. (OTCQB:BCYP), an innovator of mobile consumer activation, engagement and social advocacy solutions for manufacturers and brick-and-mortar retailers, is scheduled to host a conference call to report 2015 FYE financial results and provide a business update on Tuesday, March 22nd at 4:30 p.m. ET / 3:30 p.m. CT. CEO Andrew Levi and CFO Chris Fameree will deliver remarks followed by a question and answer session.
To access the call in the U.S. please dial Live Participant Dial In (Toll Free): 877-407-8033 and for international calls dial 201-689-8033, approximately 10 minutes prior to the start of the conference. No passcode is required. A replay will be available following the call at http://bluecalypso.com/investors/investor-events/.
About Blue Calypso, Inc. Dallas-based Blue Calypso, Inc. (OTCQB:BCYP) develops and delivers an innovative location-centric mobile shopper engagement experience for brands, retailers and consumers. The Company’s KIOSentrix® platform connects consumers to brands, drives local in-store traffic, increases shopper spend and shortens the consumer’s path-to-purchase. The Company was recently selected to Retail CIO Outlook magazine’s “Top 10 Merchandising Solution Providers – 2016”. For more information about the Company, please visit www.bluecalypso.com.
MEDIA CONTACT Rachel David [email protected] 972.499.6630 INVESTOR CONTACT Merriman Capital, Inc. Gary Abbott [email protected] (415) 248-5639


Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 



